phosphodiesterase 3 inhibitors

Preferred Label : phosphodiesterase 3 inhibitors;

MeSH definition : Compounds that specifically inhibit PHOSPHODIESTERASE 3.;

MeSH synonym : inhibitors, phosphodiesterase 3; PDE3 inhibitors; inhibitors, PDE3; phosphodiesterase type 3 inhibitors; PDE-3 inhibitors; inhibitors, PDE-3; PDE 3 inhibitors; Phosphodiesterase Type 3 Inhibitor; PDE3 Inhibitor; Inhibitor, PDE3; Phosphodiesterase 3 Inhibitor; 3 Inhibitor, Phosphodiesterase; Inhibitor, Phosphodiesterase 3;

Is substance : O;

action pharmacologique : O;

Détails

Origin ID

D058987;

UMLS CUI

C2267032;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Indexing information
- 5-(1-(3-fluorophenyl)-1H-pyrazol-4-yl)-2H-tetrazole [MeSH Supplementary Concept]
MeSH Descriptor(s) used for indexing
- cyclic nucleotide phosphodiesterases, type 3 [MeSH Descriptor]
Record concept(s)
- phosphodiesterase 3 inhibitors [MeSH concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- Cilostazol [MeSH Descriptor]
- Simendan [MeSH Descriptor]
- amrinone [MeSH Descriptor]
- enoximone [MeSH Descriptor]
- milrinone [MeSH Descriptor]
- olprinone [MeSH Supplementary Concept]

Position du mot-clé dans l'(les) arborescence(s) :

Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients